Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Thromboembolism 1Thrombocytopenia 1Neoplasms 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × apixaban × 90 days × Clear all
NCT07493304 2026-05-29

ROXI-CAT-II

Regeneron Pharmaceuticals

Phase 3 Recruiting
1,600 enrolled
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT06886516 2026-04-15

Apixaban in Thrombocytopenia

Beth Israel Deaconess Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Classical hematology

Pulmonary Embolism, Thrombocytopenia, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡